List of approved countries for authorised human medicines on exit day
Updated 9 October 2019
© Crown copyright 2019
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/list-of-approved-countries-for-authorised-human-medicines-in-a-no-deal-scenario/list-of-approved-countries-for-authorised-human-medicines-on-exit-day
1. List of exit day approved countries
If the UK leaves the EU without a deal, the Human Medicines Regulations 2012 will refer to lists of approved countries for:
- Importation of medicines under a wholesale dealer’s licence (“approved country for import list”)
- Batch testing of medicines (“approved country for batch testing list”)
- Manufacturing of active substances with regulatory standards equivalent to the UK (“approved country for active substances list”)
On exit day, the UK will accept batch testing (quality control testing), certification by a Qualified Person and Active Substance manufacture from countries specified in these lists. This will be subject to any relevant conditions or restrictions that existed in arrangements with the EU immediately before exit day.
This will be reviewed at least every 3 years (but no earlier than 2 years after exit day in the case of EEA States on those lists).
2. Approved country for import list
Regulation 18A of the Human Medicines Regulations 2012 will allow importation of human medicines under a UK wholesale dealer’s licence from the following countries, provided that the UK wholesale dealer confirms that each batch has been certified by a Qualified Person (QP) in a listed country. Further guidance is available on importation of medicines for a listed country and the steps required to verify QP certification.
2.1 EU countries
- Austria
- Belgium
- Bulgaria
- Croatia
- Republic of Cyprus
- Czech Republic
- Denmark
- Estonia
- Finland
- France
- Germany
- Greece
- Hungary
- Ireland
- Italy
- Latvia
- Lithuania
- Luxembourg
- Malta
- Netherlands
- Poland
- Portugal
- Romania
- Slovakia
- Slovenia
- Spain
- Sweden
2.2 The European Economic Area (EEA)
EU countries, plus Iceland, Liechtenstein and Norway.
3. List of countries approved for Batch testing
Batch testing (quality control testing) of human medicines will be accepted from the following countries under paragraph 14(1)(b) of Schedule 7 of the Human Medicines Regulations 2012:
3.1 EU countries
- Austria
- Belgium
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Finland
- France
- Germany
- Greece
- Hungary
- Ireland
- Italy
- Latvia
- Lithuania
- Luxembourg
- Malta
- Netherlands
- Poland
- Portugal
- Romania
- Slovakia
- Slovenia
- Spain
- Sweden
3.2 The European Economic Area (EEA)
EU countries, plus Iceland, Liechtenstein and Norway.
3.3 Non-EEA countries with existing EU Mutual Recognition Agreements (MRA)
- Australia
- Canada
- Israel
- Japan
- New Zealand
- Switzerland United States of America.
There will be the same restrictions on the acceptance of batch testing from non-EEA countries as were in place immediately before exit day. The products not included in the scope of these agreements are:
Australia
- Advanced Therapy Medicinal Products
Canada
- Medicinal products derived from human blood or blood plasma
- Advanced Therapy Medicinal Products
Israel
- Medicinal gases
- Homeopathic products
- Medicinal products derived from human blood or blood plasma
- Advanced Therapy Medicinal Products
Japan
- Medicinal gases
- Medicinal products derived from human blood or blood plasma
- Advanced Therapy Medicinal Products
New Zealand
- Advanced Therapy Medicinal Products
United States of America
- Vaccines
- Advanced Therapy Medicinal Products
- Medicinal products derived from human blood or blood plasma
4. List of countries with equivalent regulatory standards for the manufacture of active substances
Regulation 450 of the amended Human Medicines Regulations 2012 will require the competent authority of the exporting country of the active substance manufacturer to issue a written confirmation of good manufacturing practice and regulatory oversight equivalent to that of the UK.
This is not required if the active substance manufacturer is in an approved country.
These approved countries are:
4.1 EU countries
- Austria
- Belgium
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Finland
- France
- Germany
- Greece
- Hungary
- Ireland
- Italy
- Latvia
- Lithuania
- Luxembourg
- Malta
- Netherlands
- Poland
- Portugal
- Romania
- Slovakia
- Slovenia
- Spain
- Sweden
4.2 The European Economic Area (EEA)
EU countries, plus Iceland, Liechtenstein and Norway.
4.3 Non-EEA countries
- Australia
- Brazil
- Israel
- Japan
- Switzerland
- United States of America.